APRE

Aprea Therapeutics, Inc.

5.20 USD
-0.15 (-2.80%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aprea Therapeutics, Inc. stock is up 1.56% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 May’s closed higher than April. 100% of analysts rate it a buy.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia (AML)